GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US. The programme represents the largest capital spend by ...
GlobalData on MSN1mon
GSK pumps up to $800m for US manufacturing site upgradeThe funding, which brings GSK’s expenditure in US manufacturing capabilities close to $1.3bn, will establish a new vaccines ...
Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in ...
The site at Ulverston currently belongs to GlaxoSmithKline (GSK), which ... to establish the area as a "nationally-advanced manufacturing location". The proposals include "flexible office space ...
WGAL Lancaster-Harrisburg on MSN1mon
Vaccine manufacturer announces expansion at Susquehanna Valley facilityVaccine manufacturer GSK announced Thursday it will invest $800 million to expand its Marietta location ... the largest ...
GSK said the vast majority of the products will be for export to global markets, adding that the investment builds on the company’s existing network of nine UK manufacturing sites, employing ...
SINGAPORE - The expansion of British drugmaker GSK’s facility in Tuas has earned the title of Singapore’s largest vaccine production site based on a cumulative investment of some $850 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback